Drug substance for the ALZ-101 vaccine is now produced – meets the requirements of the upcoming clinical Phase 1b study
Alzinova AB has secured materials for the clinical Phase 1b study through the manufacturing of the drug substance for the oligomer-specific vaccine ALZ-101. The high-purity material meets the quality requirements of the clinical trial. The clinical trial with ALZ-101 on Alzheimer's disease patients is expected to start during the second quarter of 2021.“We are very pleased that the drug substance for the upcoming clinical Phase 1b study with ALZ-101 is now manufactured. For us, this is an important milestone, showing that the drug substance for the ALZ-101 vaccine can be manufactured to a